Tg Therapeutics (TGTX) Other financing activities (2013 - 2026)

Tg Therapeutics' Other financing activities history runs 13 years deep, the most recent figure standing at $763000.0 for Q1 2026.

• In Q1 2026, Other financing activities rose 3533.33% year-over-year to $763000.0; the TTM figure through Mar 2026 stood at $2.3 million (up 150.33% YoY), while the FY2025 annual figure was $1.5 million, up 69.97% from the prior year.
• Other financing activities for Q1 2026 stood at $763000.0, down from $1.5 million in the prior quarter.
• The five-year high for Other financing activities was $1.5 million in Q4 2025, with the low at -$453000.0 in Q3 2025.
• The 5-year median for Other financing activities is $281000.0 (2023), against an average of $330062.5.
• The sharpest annual moves came in 2022 and 2026: Other financing activities plunged 620.0% in 2022, then soared 3533.33% in 2026.
• Tg Therapeutics' Other financing activities stood at $584000.0 in 2022, then declined by 28.08% to $420000.0 in 2023, then grew by 29.76% to $545000.0 in 2024, then surged by 177.25% to $1.5 million in 2025, then sank by 49.5% to $763000.0 in 2026.
• Business Quant data shows TGTX's Other financing activities at $763000.0 in Q1 2026, $1.5 million in Q4 2025, and -$453000.0 in Q3 2025.